Decent Holding Inc. - Class A Ordinary Shares (DXST)
Live price chart, market sentiment, and community perspectives for Decent Holding Inc. (NASDAQ: DXST).
Live price chart, market sentiment, and community perspectives for Decent Holding Inc. (NASDAQ: DXST).
On our desk, DXST is drawing significant retail chatter with roughly 106 daily Reddit mentions across subplots like wallstreetbets. While social sentiment scores hold steady around a bullish 62/100, we have to contrast this speculative interest against a modest $6 million market cap and compressed valuation metrics like a P/S near 0.35.
Looking at the balance sheet constraints from a risk management lens, the company reported about $1.7 million in cash and cash equivalents alongside roughly $3.4 million in other payables and total liabilities climbing toward $19.6 million. Even with $7.0 million raised from financing activities, short-term liquidity execution remains a primary watchpoint.
Watching the price action, DXST has been consolidating in a tight $2.50 to $2.70 range after testing premarket spikes above $3.30 following strategic expansion announcements. Day-trading potential remains elevated, but fundamental technical momentum has stalled out according to our AI scoring models which peg the stock at a neutral 50 Hold.
From an operational angle, the pivot toward digital health and senior healthcare services in China is delivering tangible top-line metrics. The expansion to 623 operation centers and over 210,000 paid members demonstrates active demand, driving $3.5 million in high-margin training revenue during the first half of fiscal 2026.
From a market positioning perspective, the March 16 reverse share split and subsequent July shareholder approvals have restructured capital foundations. Investors are weighing these structural changes against the company's dual exposure to wastewater treatment, which brought in $9.2 million, and its expanding elderly care network.
Analyzing the income statement details for the six months ended April 30, 2026, total revenue reached $18.6 million, up from $5.5 million. Gross profit expanded 310.3% to $6.2 million, lifting margins to 33.4%. However, operating expenses scaling to $7.1 million kept the firm in a net loss position of $1.1 million.
Explore plasma cleansing, somatic organ swaps, and BCI.